Clinical Research in Oncology

Perspective Open Access

Measurable residual disease as a surrogate endpoint for overall survival in acute myeloid leukemia: a call to action

Marie-Helene Blanchet Zumofen , Vicky Huang , Kathryn Matt , Neerav Monga , Thomas Prebet , Thomas J. Prior , Bourras-Rezki Bengoudifa , Brenda Chyla , Carole Longson , Beate Wulff , Reshma Patel , Daniel Lopes de Menezes

The standardization and implementation of new endpoints are crucial for the development of novel therapeutic agents. These endpoints help streamline clinical development while maintaining high standards of care for innovative treatments, ultimately leading to improved patient outcomes. 

Commentary Open Access

Pancreatic cancer therapy in the era of precision oncology

Sakarie Mustafe Hidig

Pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDAC), remains one of the most lethal malignancies, characterized by late diagnosis, aggressive tumor biology, and profound resistance to conventional therapies. Despite advances in surgical techniques and combination chemotherapy regimens such as FOLFIRINOX and gemcitabine-based therapies, survival outcomes remain poor, with five-year survival rates barely exceeding 10%. 

Case Series Open Access

Five-year recurrence-free survival in glioblastoma: A case series of eight patients treated with a traditional herbal adjunct

Mahmood Mirzaee

Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite standard treatment. This case series presents eight patients with confirmed GBM who received traditional herbal preparation in addition to standard therapy. Over a follow-up period of two to five years, none showed signs of tumor recurrence on serial MRI.

Original Research Open Access

Clinical validation of a metabolomics-based multi-cancer early detection test

M. Gopichand , A. Gupta , K. K. Mittal , A. Ahmad , M. V. Kalloli , P. R. Kumar , P. P. Lad , I. Longkumer , R. V. Nagarkar , W. R. Narayan , R. Neve , S. K. Pal , K. V. S. Rao , D. Sadhupati , G. Sagar , Z. Siddiqui , V. Tripathi , N. M. Saquib , V. P. Singh

Multi-cancer detection (MCD) tests can improve the efficacy of existing screening tests by detecting a greater number of cancers. For exerting a clinical impact, however, it is important that the MCD is able to accurately detect early-stage cancers, a feature that is limited in currently available tests.

Commentary Open Access

Predicting GIST mitotic index before surgery: Where conventional CT fits in oncology precision?

Junjie An , Yingzheng Ren , Yang Yang , Yonghong Dong

Risk stratification for gastrointestinal stromal tumor (GIST) depends on postoperative mitotic index (MI), a histologic marker unavailable before surgery to guide neoadjuvant therapy and operative strategy. In 2020, Ren et al.